Skip to main content
Year archive

Xbrane Biopharma — 2021 filings

All 39 regulatory filings released by Xbrane Biopharma (XBRANE) in 2021, sourced directly from the official regulator.

39 Filings
2021 Period
2021 filings (39)
Filing Released Lang
Xbrane initierar utveckling av två nya biosimilarkandidater och bygger en biosimilarportfölj inom onkologi som adresserar €23 miljarder i årlig försäljning på referensprodukterna
Regulatory Filings
2021-12-13 Swedish
Xbrane has initiated development of two new biosimilar candidates, building an oncology biosimilar portfolio targeting €23 billion in annual reference product sales
Regulatory Filings
2021-12-13 English
Interim / Quarterly Report 2021
Interim / Quarterly Report 9M 2021
2021-10-29 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report 9M 2021
2021-10-29 English
Xbrane Biopharma presenterar valberedning
Board/Management Information
2021-10-18 Swedish
Xbrane Biopharma presents Nomination Committee
AGM Information
2021-10-18 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Q2 2021
2021-08-13 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report H1 2021
2021-08-13 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-08-06 English
Change of number of shares and votes in Xbrane
Declaration of Voting Results & Voting Rights Announcements
2021-07-31 English
Förändrat antal aktier och röster i Xbrane
Declaration of Voting Results & Voting Rights Announcements
2021-07-31 Swedish
Major Shareholding Notification 2021
Major Shareholding Notification
2021-07-08 English
Xbrane Biopharma has carried out a directed share issue raising gross proceeds of SEK 380 millions
Share Issue/Capital Change
2021-06-30 English
Xbrane Biopharma har genomfört en riktad nyemission och tillförs därigenom 380 miljoner kronor
Share Issue/Capital Change
2021-06-30 Swedish
Xbrane Biopharma announces intention to carry out a directed share issue
Capital/Financing Update
2021-06-30 English
Xbrane Biopharma offentliggör avsikt att genomföra en riktad nyemission
Capital/Financing Update
2021-06-30 Swedish
CHANGE OF NUMBER OF SHARES AND VOTES IN XBRANE
Declaration of Voting Results & Voting Rights Announcements
2021-06-30 English
FÖRÄNDRAT ANTAL AKTIER OCH RÖSTER I XBRANE
Share Issue/Capital Change
2021-06-30 Swedish
Xlucane™ når det primära effektmåttet i den registreringsgrundande fas III studien för Xlucane™ - ansökan om marknadsgodkännande i EU och USA planeras till andra halvåret 2021
Regulatory Filings
2021-06-27 Swedish
Xlucane™ meets the primary endpoint in the pivotal Phase III trial with Xlucane™ – regulatory submission in EU and US planned for second half of 2021
Regulatory Filings
2021-06-27 English
Xbrane announces ambition to generate positive operating cash flow monthly by late 2023/early 2024 and to initiate one new biosimilar development program per annum.
Regulatory Filings
2021-05-16 English
Xbrane uttalar ambition att generera positivt operationellt kassaflöde på månadsbasis vid slutet av 2023/ början av 2024 och att initiera ett nytt biosimilarutvecklingsprojekt per år.
Management Reports
2021-05-16 Swedish
Announcement from Xbrane Biopharma's annual general meeting
AGM Information
2021-05-06 English
Kommuniké från årsstämman i Xbrane Biopharma
AGM Information
2021-05-06 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q1 2021
2021-05-06 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q1 2021
2021-05-06 English
Annual Report 2021
Annual Report
2021-03-31 Swedish
Annual Report 2020
Annual Report FY 2020
2021-03-31 English
Notice of annual general meeting in Xbrane Biopharma AB
AGM Information
2021-03-30 English
Kallelse till årsstämma i Xbrane Biopharma AB
AGM Information
2021-03-30 Swedish
Major Shareholding Notification 2021
Major Shareholding Notification
2021-03-04 English
Earnings Release 2020
Earnings Release Q4 2020
2021-02-26 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Q4 2020
2021-02-26 English
To further focus on becoming a world leading biosimilar developer Xbrane enters a non-binding term-sheet to divest its Italian subsidiary Primm Pharma
M&A Activity
2021-02-24 English
För att fullt ut fokusera på att bli en världsledande utvecklare av biosimilarer har Xbrane ingått ett icke-bindande avtal om avyttring av sitt dotterbolag Primm Pharma
M&A Activity
2021-02-24 Swedish
Xbrane appoints Anette Lindqvist as new Chief Financial Officer & Head of Investor Relations
Board/Management Information
2021-01-11 English
Xbrane utser Anette Lindqvist till ny Chief Financial Officer & Head of Investor Relations
Board/Management Information
2021-01-11 Swedish
Xbrane re-negotiates pre-existing IP license agreement with Vaxiion Therapeutics
Regulatory Filings
2021-01-05 English
Xbrane omförhandlar befintligt patentlicensavtal med Vaxiion Therapeutics
Regulatory Filings
2021-01-05 Swedish